- msco annual meeting -
Join your oncology colleagues and expert faculty for the MSCO 2023 Annual Meeting that will be held at the Boston Marriott Newton on Friday, November 17, 2023.
By attending our annual meeting, you can earn CME credit, as well as interact with faculty in Q&A designed to answer your more pressing questions.
All are welcome to attend - physicians, nurses, support staff, researchers, social workers, and previous award recipients.
Food, Drinks and NetWorking
Nancy U. Lin, MD
Associate Chief, Division of Breast Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA
Director, Metastatic Breast Cancer Program, DFCI
Director, Program for Patients with Breast Cancer Brain Metastases, DFCI
Medical Director, Breast Oncology Center Translational Hub, DFCI
Associate Professor of Medicine, Harvard Medical School
Dr. Lin is a medical oncologist and clinical investigator specializing in the care of patients with breast cancer. She received her medical degree from Harvard Medical School and trained in internal medicine at Brigham & Women’s Hospital prior to completion of fellowships in medical oncology and hematology at Dana-Farber/Mass General Brigham. Dr. Lin is an internationally recognized leader in the field of breast cancer brain metastases. She has led studies resulting in new treatment options for patients living with brain metastases (lapatinib, neratinib, tucatinib, high-dose trastuzumab, trastuzumab deruxtecan) and collaborates with laboratory-based investigators to bring the most promising regimens into clinical trials. Dr. Lin is the founder and director of the EMBRACE (Ending Metastatic Breast Cancer for Everyone) metastatic breast cancer program at Dana-Farber, which encompasses a comprehensive clinical program including personalized matching for clinical services and clinical trials, patient education, and coordination or care with community-based oncologists. The accompanying EMBRACE metastatic breast cancer research program is designed to catalyze clinical and translational research focused on advanced breast cancer, with projects ranging from quality of care, health care disparities, treatment resistance, and biomarker development.